OBJECTIVE: To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-kappaB, on end-organ disease in the MRL-Fas(lpr) murine model of systemic lupus erythematosus (SLE). METHODS: Eight-week-old female MRL/Fas(lpr) mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclophosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, brachial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. RESULTS: DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas(lpr) mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Fas(lpr) mice responds differentially to NF-kappaB inhibitor. CONCLUSION: DCB-3503 causes significant abrogation of skin disease in MRL/Fas(lpr) mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.
OBJECTIVE: To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-kappaB, on end-organ disease in the MRL-Fas(lpr) murine model of systemic lupus erythematosus (SLE). METHODS: Eight-week-old female MRL/Fas(lpr) mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclophosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, brachial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. RESULTS:DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas(lpr) mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Fas(lpr) mice responds differentially to NF-kappaB inhibitor. CONCLUSION:DCB-3503 causes significant abrogation of skin disease in MRL/Fas(lpr) mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.
Authors: Jason S Knight; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Carolyne K Smith; Jeffrey B Hodgin; Paul R Thompson; Mariana J Kaplan Journal: Ann Rheum Dis Date: 2014-08-07 Impact factor: 19.103
Authors: Yuan Liu; Josephine Ye; Luisa Shin Ogawa; Takayo Inoue; Qin Huang; John Chu; Richard C Bates; Weiwen Ying; Andrew J Sonderfan; Patricia E Rao; Dan Zhou Journal: PLoS One Date: 2015-05-14 Impact factor: 3.240
Authors: Rafael González-Tajuelo; Javier Silván; Alicia Pérez-Frías; María de la Fuente-Fernández; Reyes Tejedor; Marina Espartero-Santos; Esther Vicente-Rabaneda; Ángeles Juarranz; Cecilia Muñoz-Calleja; Santos Castañeda; Carlos Gamallo; Ana Urzainqui Journal: Sci Rep Date: 2017-02-02 Impact factor: 4.379
Authors: Ying Wang; Sangwon Lee; Ya Ha; Wing Lam; Shao-Ru Chen; Ginger E Dutschman; Elizabeth A Gullen; Susan P Grill; Yao Cheng; Alois Fürstner; Samson Francis; David C Baker; Xiaoming Yang; Kuo-Hsiung Lee; Yung-Chi Cheng Journal: Sci Rep Date: 2017-08-30 Impact factor: 4.379